EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study

Yanxin Chen, Yuxi Luo, Yunwei Liu, Daya Luo, Anwen Liu

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03899-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yanxin Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors, Mice, Inbred C57BL, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Graduate Innovation Program of Nanchang University, National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsMice, Inbred C57BLProgrammed Cell Death 1 ReceptorAnimalsMiceHumansMyocarditisMaleInterleukin-6Cell ProliferationFemaleLung NeoplasmsDisease Models, Animal

Stichwörter der Autor:innen

IL-6Immune checkpoint inhibitorsMyocardial inflammatory injuryTocilizumab

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorInterleukin-6

Autor:innen und Institutionen

  • Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.
  • Department of Radiotherapy, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410000, Hunan Province, China.
  • Jiangxi Key Laboratory of Clinical Translational Cancer Research, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.
  • Radiation Induced Heart Damage Institute, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.
  • Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang, 330006, Jiangxi Province, China.
  • Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China. awliu666@163.com.

Förderung

  • Graduate Innovation Program of Nanchang University
  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangxi Province
  • Wu Jieping Medical Foundation

Zitieren

APA

Chen, Y., Luo, Y., Liu, Y., Luo, D., & Liu, A. (2025). Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03899-9

Vancouver

Chen Y, Luo Y, Liu Y, Luo D, Liu A. Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03899-9

BibTeX
@article{Chen2025,
  author = {Chen, Yanxin and Luo, Yuxi and Liu, Yunwei and Luo, Daya and Liu, Anwen},
  title = {Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03899-9}
}
Kostenlos starten →